Research Paper
A novel cuproptosis-associated immune risk model for prediction of prognosis and response to immunotherapy in triple-negative breast cancer
Figure 8. Functional analyses for patients in two risk groups. (A) GO analysis based on differentially expressed genes in low-risk samples. (B) GO analysis based on differentially expressed genes in high-risk samples. (C) Identifying KEGG pathways significantly enriched in the low-risk samples by GSEA. (D) Identifying KEGG pathways significantly enriched in the high-risk samples by GSEA. (E) Comparing the scores of signatures relating to tumor metabolism between low- and high-risk groups. (*P<0.05, **P< 0.01, ***P< 0.001).